Last updated: 2026-10-16 01:24:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Castle Biosciences, Inc. (CSTL) operates in the SERVICES-MEDICAL LABORATORIES sector and is listed on NASDAQ. The stock is currently priced at $33.84, with a market capitalization of $1.00B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $17.72 to $44.28. This page covers its latest market performance, valuation, price trends and company information.
$1.00B | |
$33.81 | |
$107.69 | |
$2.26 | |
$33.11 | |
140.84K | |
404.25K | |
-- | |
$44.28 | |
$17.72 | |
-- | |
-- |
Castle Biosciences, Inc. (CSTL) last closed at $33.11 as of 2026-10-15 23:31:00, unchanged from the previous close of $33.11.
During the latest regular trading session, CSTL traded between $2.26 and $107.69, with a volume of 140.84K shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Castle Biosciences, Inc. (CSTL) moved from $33.36 to $33.84, representing a gain of 1.43% ($0.48).
The stock traded between $32.23 and $37.99 during the period. The latest price is near the lower end of the 7-day range, indicating moderate upward.
The average daily volume was 329.65 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 60.7%
CSTL is currently trading at $33.84, placing it 60.7% of the way from its 52-week low of $17.72 to its 52-week high of $44.28. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
| Industry | SERVICES-MEDICAL LABORATORIES |
| Employees | 1002 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Castle Biosciences, Inc. (CSTL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.